Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Development and characterization of a pan-flavivirus vaccine candidate

Project description

New vaccine targets multiple mosquito-borne viruses

Mosquito-borne flaviviruses, including dengue, yellow fever, Zika, and West Nile, infect half a billion people annually, causing 250 000 deaths. With global changes intensifying, these viruses are spreading rapidly, raising the risk of future epidemics and pandemics. Despite the urgency, no effective interventions exist against all flaviviruses, and current vaccines carry serious safety concerns. To address these issues, the EU-funded FLAVIVACCINE project aims to change this by developing a broad-spectrum, mosquito saliva-targeted vaccine that protects against multiple flaviviruses. Leveraging an experimentally proven concept, FLAVIVACCINE’s interdisciplinary team from seven countries will prepare the vaccine for clinical trials, offering a promising solution to bolster global health security.

Objective

Dengue, yellow fever, Zika, and West Nile viruses are mosquito-borne flaviviruses and global public health burdens that infect half a billion people annually, causing 250,000 deaths, and threaten nearly the entire human population. In a context of human-driven global changes, these threats will intensify with larger and more frequent epidemics, potentially leading to pandemics, will expand with geographic spreading of the mosquito vectors, and will multiply with the likely emergence of yet-unknown flaviviruses. Improving pandemic preparedness and response to these emerging and re-emerging diseases is a top priority both for the EU and WHO. However, there are no effective interventions against all flaviviruses and current vaccines targeting flaviviral proteins have severe safety issues. FLAVIVACCINE’s high-impact/low-risk/disruptive ambition is to develop a novel, broad-spectrum, mosquito saliva-targeted vaccine candidate that protects against multiple different flaviviruses and is ready for clinical evaluation by building upon an experimentally-validated proof-of-concept. FLAVIVACCINE will define the immunogenicity of the pan-flavivirus target, develop and characterize a vaccine candidate against multiple flaviviruses, and prepare it for clinical evaluation. To reach these goals, FLAVIVACCINE creates a unique interdisciplinary environment of ten public and private institutions, including Universities, Research Institutions and a Vaccine Developer, from seven countries to cover all the required scientific expertise and knowledge in cell biology, virology, immunology and vaccinology. The pan-flavivirus vaccine candidate that will be validated against dengue, yellow fever, Zika and West Nile diseases in several preclinical models, together with the knowledge and networks resulting from FLAVIVACCINE, will have short- and long-term impact on the EU ability to combat epidemic and pandemic viral threats, and protect communities and citizens in the EU and around the world.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2023-DISEASE-03

See all projects funded under this call

Coordinator

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
Net EU contribution
€ 1 829 196,25
Address
BOULEVARD DE DUNKERQUE 44 CS 90009
13572 Marseille
France
Region
Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône
Activity type
Research Organisations
Links
Total cost
€ 1 829 196,25

Participants (9)

Partners (2)